Oxford Finance has announced a $15 million round of debt financing for XDx. Silicon Valley Bank acted as co-lender in this transaction. XDx is based in Brisbane, California and is a molecular diagnostics company. Proceeds of the loan will be used for working capital and to fund the development of new diagnostic applications.

Vitae Pharmaceuticals has secured a $15 million round of debt financing from Oxford Finance, a specialty finance firm that provides senior debt to life sciences and healthcare services companies and Silicon Valley Bank. The funds will be used to support the progress of Vitae’s drug pipeline, which includes treatments for chronic kidney disease, diabetes, Alzheimer’s [...]

Radius Health Inc. said Tuesday that it closed a $91 million third round of financing. The round includes $66 million in equity financing, and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance for a $25 million multi-draw term loan facility. Five new investors–including BB Biotech AG, Brookside Capital, Saints Capital, Nordic Bioscience, and Ipsen Pharma SAS–joined existing investors MPM Capital, BB Biotech Ventures, MPM Bio IV NVS Strategic Fund, The Wellcome Trust, HealthCare Ventures, and Scottish Widows Investment Partnership in the equity portion of the round. Radius Health is based in Cambridge, Mass. Radius also announced that immediately following the initial closing of the financing, it merged with MPM Acquisition Corp., an unlisted public reporting shell company. The combined company will go by the name Radius Health. Radius is a developer of drug therapies for osteoporosis and women’s health.

Oxford Finance, a company that makes loans to life science and healthcare companies, has raised $460 million from Sumitomo Corp. and private equity firm Welsh, Carson, Anderson & Stowe, Reuters reported. Oxford Finance has been majority-owned by Sumitomo since 2004. The company will use the new money, in part, to expand its portfolio.